Complex airway disease: An approach to assessment and management

The Lancet Respiratory Medicine

Volumn 1, Issue 1, 2013, Pages 84-90

  Pavord, Ian D ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; GOLIMUMAB; LONG ACTING DRUG; MACROLIDE; MEPOLIZUMAB; MUSCARINIC RECEPTOR BLOCKING AGENT; OMALIZUMAB; SALBUTAMOL; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY OBSTRUCTION; ASTHMA; BREATHING EXERCISE; BRONCHIAL THERMOPLASTY; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COUGHING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESEARCH; HIGH RISK POPULATION; HUMAN; LOEFFLER PNEUMONIA; LUNG EMPHYSEMA; LUNG INJURY; LUNG RESECTION; NEUTROPHILIA; NONHUMAN; NOTE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY REHABILITATION; RESPIRATION CONTROL; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION; THORAX SURGERY; TREATMENT PLANNING; WEIGHT REDUCTION; CLASSIFICATION; RESPIRATORY TRACT DISEASES;

HUMANS; PHENOTYPE; RESPIRATORY TRACT DISEASES; RISK FACTORS;

EID: 84880041974     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(12)70049-8     Document Type: Note

References (56)

1. Rackemann FM A clinical survey of 1074 patients with asthma followed for two years. J Lab Clin Med 1927, 12:1185-1197.
2. Pavord ID, Birring SS, Berry M, Green RH, Brightling CE, Wardlaw AJ Multiple inflammatory hits and the pathogenesis of severe airway disease. Eur Respir J 2006, 27:884-888.
3. Pavord ID, Haldar P, Bradding P, Wardlaw AJ Mepolizumab in refractory eosinophilic asthma. Thorax 2010, 65:370.
4. Pavord ID, Wardlaw AJ The A to E of airway disease. Clin Exp Allergy 2010, 40:62-67.
5. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549-558.
6. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178:218-224.
7. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010, 181:315-323.
8. Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011, 66:430-437.
9. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000, 162:2341-2351. American Thoracic Society.
10. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011, 378:983-990.
11. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006, 27:483-494.
12. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360:1715-1721.
13. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011, 184:662-671.
14. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000, 356:1480-1485.
15. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007, 29:906-913.
16. Global strategy for diagnosis, management and prevention of COPD GOLD, (accessed Aug 24, 2012). http://www.goldcopd.org/Guidelines/guidelines-resources.html.
17. Pavord ID, Chung KF Management of chronic cough. Lancet 2008, 371:1375-1384.
18. Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007, 356:1327-1337.
19. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003, 348:2059-2073.
20. Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC Smoking and airway inflammation in patients with mild asthma. Chest 2001, 120:1917-1922.
21. Brightling CE, Ward R, Goh KL, Wardlaw AJ, Pavord ID Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 1999, 160:406-410.
22. Morice AH, Lowry R, Brown MJ, Higenbottam T Angiotensin-converting enzyme and the cough reflex. Lancet 1987, 330:1116-1118.
23. Sovani MP, Whale CI, Oborne J, et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. Br J Gen Pract 2008, 58:37-43.
24. Fairs A, Agbetile J, Hargadon B, et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010, 182:1362-1368.
25. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004, 170:583-593.
26. Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003, 111:952-957.
27. Busse W, Gergen PJ, Calatroni A Anti-IgE for asthma in inner-city children. N Engl J Med 2011, 364:2557-2558.
28. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
29. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
30. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
31. Koyama H, Geddes DM Erythromycin and diffuse panbronchiolitis. Thorax 1997, 52:915-918.
32. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008, 177:148-155.
33. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698.
34. Thomson NC, Spears M The influence of smoking on the treatment response in patients with asthma. Curr Opin Allergy Clin Immunol 2005, 5:57-63.
35. Thomson NC, Chaudhuri R, Livingston E Asthma and cigarette smoking. Eur Respir J 2004, 24:822-833.
36. Lewis S, Bennett J, Richards K, Britton J A cross sectional study of the independent effect of occupation on lung function in British coal miners. Occup Environ Med 1996, 53:125-128.
37. Venn AJ, Lewis SA, Cooper M, Hubbard R, Britton J Living near a main road and the risk of wheezing illness in children. Am J Respir Crit Care Med 2001, 164:2177-2180.
38. Reed CE, Milton DK Endotoxin-stimulated innate immunity: a contributing factor for asthma. J Allergy Clin Immunol 2001, 108:157-166.
39. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
40. Lemanski RJ Is asthma an infectious disease?. Chest 2003, 123(suppl 3):385S-390S.
41. Birring SS, Brightling CE, Bradding P, et al. Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study. Am J Respir Crit Care Med 2002, 166:1078-1083.
42. Birring SS, Patel RB, Parker D, et al. Airway function and markers of airway inflammation in patients with treated hypothyroidism. Thorax 2005, 60:249-253.
43. Camus P, Colby TV The lung in inflammatory bowel disease. Eur Respir J 2000, 15:5-10.
44. Kanazawa H, Mamoto T, Hirata K, Yoshikawa J Interferon therapy induces the improvement of lung function by inhaled corticosteroid therapy in asthmatic patients with chronic hepatitis C virus infection: a preliminary study. Chest 2003, 123:600-603.
45. Kanazawa H, Hirata K, Yoshikawa J Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients. Chest 2003, 123:596-599.
46. Caselli M, Zaffoni E, Ruina M, et al. Helicobacter pylori and chronic bronchitis. Scand J Gastroenterol 1999, 34:828-830.
47. Agusti A, MacNee W, Donaldson K, Cosio M Hypothesis: Does COPD have an autoimmune component?. Thorax 2003, 58:832-834.
48. Chaudhuri R, Livingston E, McMahon AD, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006, 174:127-133.
49. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994, 272:1497-1505.
50. Oxman AD, Muir DC, Shannon HS, Stock SR, Hnizdo E, Lange HJ Occupational dust exposure and chronic obstructive pulmonary disease. A systematic overview of the evidence. Am Rev Respir Dis 1993, 148:38-48.
51. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009, 179:11-18.
52. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354:697-708.
53. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60:1012-1018.
54. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
55. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176:1062-1071.
56. Saha S, Siva R, Brightling CE, Pavord ID COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition. Eur Respir J 2006, 27:863-865.